Form 4: BeiGene Director Wang Xiaodong Executes Share Sales Under 10b5-1 Plan

Director Wang Xiaodong of BeiGene, Ltd. sold a portion of his American Depositary Shares (ADS) under a pre-arranged 10b5-1 trading plan.

Summary

• Wang Xiaodong, a director at BeiGene, Ltd., executed multiple sales of American Depositary Shares (ADS) on January 7, 2025.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 12, 2024.
• A total of 41,760 ADS were acquired through the exercise of share options at a price of $6.5 per share.
• Subsequently, 41,760 ADS were sold in multiple transactions at weighted average prices ranging from $175.4573 to $179.1847.
• The sales resulted in a reduction of Wang Xiaodong's direct holdings of ADS.
• Wang Xiaodong also holds a significant number of ordinary shares indirectly through a family trust, Wang Investment LLC, and his spouse.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider trading activity. While the sale of shares by a director could be perceived negatively, the use of a 10b5-1 plan mitigates this concern. The sentiment is neutral.

Negatives

• The sale of shares by a director could be perceived negatively by some investors.

Risks

• The sale of a significant number of shares by a director could potentially signal a lack of confidence in the company's future performance.
• The market may react negatively to insider selling, potentially impacting the share price.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives and directors of publicly traded companies, including those in the biotechnology sector like BeiGene.
• Similar filings are regularly made by insiders at companies like Amgen, Gilead Sciences, and Regeneron, reflecting standard compliance with SEC regulations.
• The price range of the ADS sales is within the typical trading range for BeiGene, and the volume of shares sold is not unusual for insider transactions.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially impacting the stock price.
• The impact on other stakeholders is likely to be minimal as this is a routine transaction.

Key Dates

Keywords

BeiGene, Wang Xiaodong, American Depositary Shares, ADS, Share Sale, 10b5-1 Trading Plan, Insider Trading, Director, Share Options